Oculis
despite new treatment options patient satisfaction remains a challenge era no | Oculis
Company
Deck Type
Deck date
April 2024
Slide
25 of 48
Related slides by other companies
Imara
Mergers and Acquisitions
October 2022
despite great advances a significant need remains for better treatment options for chronic myeloid leukemia | Imara
Imara
Mergers and Acquisitions
October 2022
significant need remains for more treatment options for | Imara
Exscientia
Investor Presentation
November 2023
exalt study results | Exscientia
Erasca
Investor Presentation
November 2023
phase patients continuing on treatment on potential for confirmation of dor and advantage in seacraft | Erasca
Other recent decks by Oculis
See all presentations (7 decks)
Results
August 2023
Investor Presentation
July 2023
Investor Conference
June 2023
Results
May 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io